Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(25%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(1)

Detailed Status

Completed3

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

completed375%

terminated125%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_1

Safety Study of AMG 557 in Subjects With Lupus Arthritis

NCT01683695

completedphase_1

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus

NCT02391259

terminatedphase_1

Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus

NCT01389895

completedphase_1

A Study of AMG 557 in Adults With Systemic Lupus Erythematosus

NCT00774943

Clinical Trials (4)

Showing 4 of 4 trials

NCT01683695Phase 1

Safety Study of AMG 557 in Subjects With Lupus Arthritis

Completed

NCT02391259Phase 1

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus

Completed

NCT01389895Phase 1

Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus

Terminated

NCT00774943Phase 1

A Study of AMG 557 in Adults With Systemic Lupus Erythematosus

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4